But competing risk model showed male BC cohort had similar cumulative incidence of BCSD as the female BC group in both HoR+/HER2− (Figure S2B, p = 0.606) and HoR+/HER2+ group (Figure S2C, p = 0.277). Here, ERBB2 is linked to breast cancer.